Jul 2026
Abstract B031: MetAP2 inhibition by evexomostat (SDX-7320) decreases EZH2 and c-Myc and significantly prolongs survival in enzalutamide-resistant and neuroendocrine prostate cancer models
Results show that inhibition of METAP2 with SDX-7320 is a novel approach to treat ARPI-resistant as well as aggressive forms of prostate cancer warranting immediate clinical translation.
Peter Cornelius, D. Laurencia, J. Gunter et al.
· Clinical Cancer Research · 0 citations